LightDark Log in Sign up

‹ Back to screener

GRANULES.NS Granules India Ltd.

Healthcare

Price history

1M 6M 1Y 3Y Max
2025-08-21 ₹462.00
2026-08-21 ₹858.55
Change over window +85.83%

Price is the daily close from stored Kite history. The other metrics pair that daily price with the company's periodic filings — each fundamental (revenue, EPS, equity…) is held flat at its latest filed value between annual filings, so a ratio steps at each filing and moves daily only through its price term. A metric with no input on file for this company (e.g. EV/EBITDA for a bank, which has no EBIT) is shown as unavailable, never guessed. Share-count-based metrics use the latest diluted share count against split/bonus-adjusted prices.

Technical indicators

ℹ These reflect only the stock's recent price and volume behavior — not the company's fundamentals — and are not a recommendation to buy or sell. Standard published parameters are used throughout (see each chart's own label); a company with too little stored price history for a given indicator's lookback window shows that plainly below rather than a garbage or misleading value.

MACD (12,26,9), Stochastic Oscillator (14,3) and Money Flow Index (14-day) each carry their own published reference lines/bands (20/80 for the oscillator readings) where one is standard. ADX includes +DI/-DI for direction alongside trend strength; a dashed line marks the commonly published 25 "trending market" reading. ATR is shown in raw rupees here; the price/volume preset screen (below, and on the Screener page) reports it as a % of price so it's comparable across stocks at different price levels. Computed from the same stored daily OHLCV history as the price chart above — no new data source.

Delivery volume

Latest (2026-08-28) 69.6%
Trailing 20-day average 53.9%
Date Traded Qty Delivery Qty Delivery %
2026-08-28 328237 228369 69.57%
2026-08-27 1123298 626829 55.80%
2026-08-26 610115 359978 59.00%
2026-08-25 606461 362867 59.83%
2026-08-24 305614 146948 48.08%
2026-08-21 406173 238047 58.61%
2026-08-20 421049 200610 47.65%
2026-08-19 287607 147684 51.35%
2026-08-18 407105 237170 58.26%
2026-08-17 404940 182286 45.02%
2026-08-14 319463 173052 54.17%
2026-08-13 749250 360696 48.14%
2026-08-12 283049 171662 60.65%
2026-08-11 377278 170328 45.15%
2026-08-10 759536 409469 53.91%
2026-08-07 1146571 437992 38.20%
2026-08-06 447705 235812 52.67%
2026-08-05 539648 292332 54.17%
2026-08-04 827852 525607 63.49%
2026-08-03 957769 521373 54.44%

Delivery quantity/percentage from the NSE bhavcopy (DELIV_QTY/DELIV_PER) — the share of that day's traded volume that actually settled into a demat account, rather than being squared off intraday. A higher delivery percentage is commonly read as genuine accumulation/distribution rather than speculative same-day trading; this describes recent trading PATTERN, not the company itself, and is not a recommendation to buy or sell. A blank cell is a day NSE itself published no figure for, never a zero. Run python manage.py refresh_delivery_volumes --tickers GRANULES.NS to fetch more history.

Insider trading activity

Disclosed Person Category Type Mode Quantity Value (₹) Resulting stake
04 Oct 2021 Jaiashokan Velusamy Employees/Designated Employees Buy ESOP 4000 1308000 0.00% XBRL
04 Oct 2021 Chaitanya Tummala Key Managerial Personnel Buy ESOP 17660 5774820 0.02% XBRL
04 Oct 2021 Murali Mohana Raju Gottumukkala Employees/Designated Employees Buy ESOP 20000 6540000 0.02% XBRL
04 Oct 2021 Atul Dhavle Employees/Designated Employees Buy ESOP 40000 13080000 0.03% XBRL
04 Oct 2021 Guntamukkala Sivaram Prasad Employees/Designated Employees Buy ESOP 60000 19620000 0.04% XBRL
04 Oct 2021 Maddargi Devendra Kumar Employees/Designated Employees Buy ESOP 40000 13080000 0.03% XBRL
04 Oct 2021 Manikandan Ramalingam Employees/Designated Employees Buy ESOP 30000 9810000 0.02% XBRL
04 Oct 2021 Shaik Khaleel Employees/Designated Employees Buy ESOP 10000 3270000 0.00% XBRL
04 Aug 2021 Suryanarayana Murthy Ponnada Employees/Designated Employees Sell Market Sale 20000 7761149 0.05% XBRL
04 Aug 2021 Umesh Kumar Gupta Employees/Designated Employees Sell Market Sale 3000 1185000 0.00% XBRL
30 Jun 2021 Swapna Gutta Immediate relative Sell Market Sale 33000 10985000 0.01% XBRL
29 Jun 2021 Jaiashokan Velusamy Employees/Designated Employees Sell Market Sale 4000 1499100 0.00% XBRL
16 Jun 2021 K. B. Sankar Rao Director Sell Market Sale 47177 15557370 1.21% XBRL
16 Jun 2021 Swapna Gutta Immediate relative Sell Market Sale 932 309890 0.03% XBRL
10 Jun 2021 K. B. Sankar Rao Director Sell Market Sale 21400 7144461 1.23% XBRL
04 Jun 2021 K. B. Sankar Rao Director Sell Market Sale 23000 7519336 1.24% XBRL
28 May 2021 K. B. Sankar Rao Director Sell Market Sale 59800 19027912 1.25% XBRL
25 May 2021 K. B. Sankar Rao Director Sell Market Sale 109000 35012939 1.27% XBRL
21 May 2021 K. B. Sankar Rao Director Sell Market Sale 124000 40218850 1.31% XBRL
18 May 2021 K. B. Sankar Rao Director Sell Market Sale 155000 50466657 1.36% XBRL

SEBI PIT (Prohibition of Insider Trading) Regulation 7 disclosures — designated persons (promoters, directors, KMPs, and their immediate relatives) reporting their own dealing in the company's securities, as NSE publishes them. Distinct from the SAST (Regulation 29 substantial-acquisition) filings on the market-wide SAST activity page. Public record only — this is descriptive disclosure data, not a signal, and is not a recommendation to buy or sell. Run python manage.py refresh_insider_trades --tickers GRANULES.NS to fetch more.

Ratios as of FY2025-26 (Annual) · Price ₹858.15 INR (live) · fetched 2026-08-23 22:31 price stale

Extract this company (financials + ratios + citations): CSV · XLSX

Full statements: Profit & Loss · Balance Sheet · Cash Flow · Compare with 46 peers in Healthcare · Trace Score

Ratios

P/E
35.74
P/E = Price / EPS
Source trace
P/E = Price / (ProfitLossForPeriod / PaidUpValueOfEquityShareCapital ÷ FaceValueOfEquityShareCapital) → ₹858.15 / (₹5,950,210,000 / 247,800,000 shares) = ₹858.15 / ₹24.01 EPS
FY2025-26 · Annual filing
ROE
11.70%
ROE = Net Income / Shareholder Equity
Source trace
ROE = ProfitLossForPeriod / EquityAttributableToOwnersOfParent → ₹5,950,210,000 / ₹50,849,950,000 = 11.70%
FY2025-26 · Annual filing
Debt/Equity
0.26
Debt/Equity = Total Debt / Shareholder Equity
Source trace
Debt/Equity = BorrowingsCurrent + BorrowingsNoncurrent / EquityAttributableToOwnersOfParent → ₹13,381,330,000 / ₹50,849,950,000 = 0.26
FY2025-26 · Annual filing
Current Ratio
1.80
Current Ratio = Current Assets / Current Liabilities
Source trace
Current Ratio = CurrentAssets / CurrentLiabilities → ₹37,676,460,000 / ₹20,920,310,000 = 1.80
FY2025-26 · Annual filing
ROCE
14.16%
ROCE = EBIT / (Shareholder Equity + Total Debt)
Source trace
ROCE = ProfitBeforeExceptionalItemsAndTax + FinanceCosts / (EquityAttributableToOwnersOfParent + BorrowingsCurrent + BorrowingsNoncurrent) → ₹9,093,310,000 / (₹50,849,950,000 + ₹13,381,330,000) = 14.16%
FY2025-26 · Annual filing
Dividend Yield
0.17%
Dividend Yield = (Dividends Paid / Diluted Shares Outstanding) / Price

This is cash paid during the fiscal year, not a per-share rate declared for it (no such element exists in the filing data) — timing can straddle interim/final dividends across years, and pre-FY2020-21 figures may include the since-abolished Dividend Distribution Tax, reading higher than later years for that reason alone.

Source trace
Dividend Yield = (|DividendsPaidClassifiedAsFinancingActivities| / PaidUpValueOfEquityShareCapital ÷ FaceValueOfEquityShareCapital) / Price → (₹363,970,000 / 247,800,000 shares) / ₹858.15 = ₹1.47 / ₹858.15
FY2025-26 · Annual filing

Growth & earnings trend

Revenue & Profit CAGR

Revenue (3y, 3.0y actual) 5.9%
Net Profit (3y) -1.5%
Revenue (5y, 3.0y actual) 5.9%
Net Profit (5y) -1.5%
Revenue (10y, 3.0y actual) 5.9%
Net Profit (10y) -1.5%

Operating Margin Trend

Flat

FY2022-23 16.5%
FY2023-24 14.5%
FY2024-25 16.3%
FY2025-26 16.9%

ROCE Trajectory

FY2022-23 19.1%
FY2023-24 14.7%
FY2024-25 14.6%
FY2025-26 14.2%

Earnings Quality

No persistent gap detected

Net Profit CAGR -1.47% vs CFO CAGR 8.30% over 2.0y (2023-03-31 → 2025-03-31); most recent year: Net Profit +17.78% vs CFO +97.21%

Sector-Relative Percentile (Healthcare)

ROE 35th
ROCE 35th
Debt/Equity 35th
P/E 70th

Quarterly trend

Revenue Net Profit Net Profit (loss quarter)
Metric (to shareholders basis) Q4 FY2023-24 Q1 FY2024-25 Q2 FY2024-25 Q3 FY2024-25 Q4 FY2024-25 Q1 FY2025-26 Q2 FY2025-26 Q3 FY2025-26 Q4 FY2025-26 Q1 FY2026-27 Source
Revenue ₹1,175.78 Cr. ₹1,179.87 Cr. ₹966.62 Cr. ₹1,137.69 Cr. ₹1,197.43 Cr. ₹1,210.11 Cr. ₹1,296.99 Cr. ₹1,387.94 Cr. ₹1,470.61 Cr. ₹1,476.77 Cr. RevenueFromOperations
Net Profit ₹139.02 Cr. incl. minority ₹129.65 Cr. ₹134.65 Cr. ₹97.23 Cr. ₹117.60 Cr. ₹152.03 Cr. ₹110.39 Cr. incl. minority ₹112.64 Cr. ₹130.61 Cr. ₹150.21 Cr. ₹201.57 Cr. ₹179.96 Cr. ProfitOrLossAttributableToOwnersOfParent

Primary figures are Revenue from Operations and Net Profit attributable to shareholders — the basis the ratios use. Where they differ, the companion Gross revenue (incl. inter-segment) and incl. minority net profit (the totals a news headline usually quotes) are shown beneath, each traceable to its own XBRL element. Quarters shown are however many are actually stored (up to 10) — run python manage.py refresh_quarterly_trend --tickers GRANULES.NS to fetch more.

Source document — income statement (FY2025-26, raw filing line items)

View original filing on NSE ↗ NSE's own filing document, opened in a new tab — StockProof links to it, never stores a copy.

ProfitLossForPeriod5950210000.0
PaidUpValueOfEquityShareCapital ÷ FaceValueOfEquityShareCapital247800000.0
Source document — balance sheet (FY2025-26, raw filing line items)

View original filing on NSE ↗ NSE's own filing document, opened in a new tab — StockProof links to it, never stores a copy.

CurrentAssets37676460000.0
CurrentLiabilities20920310000.0
EquityAttributableToOwnersOfParent50849950000.0
BorrowingsCurrent + BorrowingsNoncurrent13381330000.0

My notes